Breaking News Instant updates and real-time market news.

PG

Procter & Gamble

$103.19

-2.85 (-2.69%)

, MRK

Merck

$74.59

1.15 (1.57%)

06:21
04/24/19
04/24
06:21
04/24/19
06:21

Procter & Gamble price target raised to $102 from $95 at UBS

UBS analyst Steven Strycula raised his price target on Procter & Gamble (PG) to $102, saying that yesterday's sell-off on investor concerns about the company's ability to boost margin "overlooks" the "upcoming inflection". The analyst keeps his Neutral rating, but notes that the Q3 margin pressure was "transitory" as it was impacted by adverse FX, commodities, higher bonus, and Merck (MRK) integration headwinds.

PG

Procter & Gamble

$103.19

-2.85 (-2.69%)

MRK

Merck

$74.59

1.15 (1.57%)

  • 24

    Apr

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

PG Procter & Gamble
$103.19

-2.85 (-2.69%)

04/08/19
WELS
04/08/19
UPGRADE
WELS
Outperform
Procter & Gamble upgraded to Outperform from Market Perform at Wells Fargo
04/08/19
WELS
04/08/19
UPGRADE
Target $115
WELS
Outperform
Procter & Gamble upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Bonnie Herzog upgraded Procter & Gamble to Outperform from Market Perform and raised her price target to $115 from $91, telling investors that while she is "late to the game," she still sees upside and believes P&G has changed and management, led by CEO David Taylor, has infused a sense of urgency and accountability into the organization. Herzog says that while it "took awhile" for consistent results to show, fundamentals appear to have turned, and sees a potential upside surprise in the third quarter on both the top and bottom line. She also views P&G as one of the few Staples companies that will be able to consistently deliver accelerating organic sales growth while expanding margins at the same time.
04/08/19
04/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) upgraded to Buy from Hold at Jefferies with analyst David Katz citing better than expected gross gaming revenue results from Macau for March and signs that suggest to him that it is reasonable to expect economic improvement throughout 2019 in China. 2. e.l.f. Beauty (ELF) upgraded to Neutral from Underweight at JPMorgan. 3. Procter & Gamble (PG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog telling investors that while she is "late to the game," she still sees upside and believes P&G has changed and management, led by CEO David Taylor, has infused a sense of urgency and accountability into the organization. 4. AMC Entertainment (AMC) upgraded to Buy from Neutral at B. Riley FBR with analyst Eric Wold saying he has an "increasingly optimistic" view of the EBITDA contribution from Stubs A-List. 5. Zillow (Z, ZG) upgraded to Outperform from Market Perform at Cowen with analyst Thomas Champion saying he believes the new duo of CEO Rich Barton and CFO Allen Parker look well suited for the "massive challenge" of leading the company through a change in business model. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/19
DZBN
04/24/19
DOWNGRADE
DZBN
Sell
Procter & Gamble downgraded to Sell from Hold at DZ Bank
MRK Merck
$74.59

1.15 (1.57%)

02/22/19
CANT
02/22/19
INITIATION
Target $95
CANT
Overweight
Merck initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen started Merck with an Overweight rating and $95 price target. The company's sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as its margin expansion opportunities, are underappreciated at current share levels, Chen tells investors in a research note. She expects upward earnings revisions and multiple expansion in 2019 to drive Merck shares higher.
03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).

TODAY'S FREE FLY STORIES

04:15
06/25/19
06/25
04:15
06/25/19
04:15
General news
FX Action: USD-CAD has become entrenched in a consolidation »

FX Action: USD-CAD has…

02:50
06/25/19
06/25
02:50
06/25/19
02:50
General news
FX Update: The dollar hit fresh lows against the euro and yen »

FX Update: The dollar hit…

02:00
06/25/19
06/25
02:00
06/25/19
02:00
General news
Asian Market Wrap: »

Asian Market Wrap: 10…

GLOG

GasLog

$13.13

-0.23 (-1.72%)

, GLOP

GasLog Partners

$21.12

-0.37 (-1.72%)

23:10
06/24/19
06/24
23:10
06/24/19
23:10
Upgrade
GasLog, GasLog Partners rating change at Stifel »

GasLog upgraded to Buy…

GLOG

GasLog

$13.13

-0.23 (-1.72%)

GLOP

GasLog Partners

$21.12

-0.37 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOP

GasLog Partners

$21.12

-0.37 (-1.72%)

, GLOG

GasLog

$13.13

-0.23 (-1.72%)

23:05
06/24/19
06/24
23:05
06/24/19
23:05
Downgrade
GasLog Partners, GasLog rating change at Stifel »

GasLog Partners…

GLOP

GasLog Partners

$21.12

-0.37 (-1.72%)

GLOG

GasLog

$13.13

-0.23 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$55.76

0.13 (0.23%)

20:40
06/24/19
06/24
20:40
06/24/19
20:40
Downgrade
Kellogg rating change at Consumer Edge »

Kellogg downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$41.15

11.87 (40.54%)

20:39
06/24/19
06/24
20:39
06/24/19
20:39
Syndicate
Krystal Biotech 2.5M share Spot Secondary priced at $40.00 »

Goldman Sachs and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

FDS

FactSet

$293.20

-4.89 (-1.64%)

, LEN

Lennar

$51.41

0.09 (0.18%)

20:25
06/24/19
06/24
20:25
06/24/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$293.20

-4.89 (-1.64%)

LEN

Lennar

$51.41

0.09 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

GNFT

Genfit

$20.19

-0.02 (-0.10%)

, GMDA

Gamida Cell

$7.21

-0.23 (-3.09%)

19:33
06/24/19
06/24
19:33
06/24/19
19:33
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Genfit (GNFT), up…

GNFT

Genfit

$20.19

-0.02 (-0.10%)

GMDA

Gamida Cell

$7.21

-0.23 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

CGC

Canopy Growth

$40.51

0.31 (0.77%)

19:20
06/24/19
06/24
19:20
06/24/19
19:20
Periodicals
Canopy Growth CEO says done buying other producers, Reuters says »

Canopy Growth CEO Bruce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$118.43

0.4 (0.34%)

19:18
06/24/19
06/24
19:18
06/24/19
19:18
Hot Stocks
Illinois American Water investing over $1.8M in Farmington Water System »

Illinois American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$359.98

0.555 (0.15%)

19:14
06/24/19
06/24
19:14
06/24/19
19:14
Periodicals
U.K.'s new F35 stealth aircraft used on operations, Telegraph says »

The U.K.'s new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.86

-0.53 (-0.76%)

19:01
06/24/19
06/24
19:01
06/24/19
19:01
Hot Stocks
Gilead, Carna Biosciences announce research and development collaboration »

Gilead and Carna…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$374.10

2.14 (0.58%)

18:59
06/24/19
06/24
18:59
06/24/19
18:59
Hot Stocks
Boeing CEO approves quarterly dividend »

Boeing Chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

GOOG

Alphabet

$1,115.75

-6.63 (-0.59%)

, GOOGL

Alphabet Class A

$1,117.00

-8.17 (-0.73%)

18:09
06/24/19
06/24
18:09
06/24/19
18:09
Periodicals
Google tells workers Pride protests are against code of conduct, Verge says »

According to internal…

GOOG

Alphabet

$1,115.75

-6.63 (-0.59%)

GOOGL

Alphabet Class A

$1,117.00

-8.17 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Oct

AAPL

Apple

$198.60

-0.17 (-0.09%)

17:53
06/24/19
06/24
17:53
06/24/19
17:53
Hot Stocks
Apple to add 2,000 employees in Seattle over next 5 years »

Seattle mayor Jenny A.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$111.25

0.08 (0.07%)

, FB

Facebook

$192.56

1.4 (0.73%)

17:51
06/24/19
06/24
17:51
06/24/19
17:51
Periodicals
Walmart in Mexico rolls out grocery delivery via WhatsApp, Reuters says »

Walmart's (WMT)…

WMT

Walmart

$111.25

0.08 (0.07%)

FB

Facebook

$192.56

1.4 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 15

    Aug

  • 13

    Nov

CAT

Caterpillar

$134.37

0.43 (0.32%)

17:46
06/24/19
06/24
17:46
06/24/19
17:46
Hot Stocks
Caterpillar awarded share of $900M Defense Logistics Agency contract »

Caterpillar is sharing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$35.14

0.06 (0.17%)

17:45
06/24/19
06/24
17:45
06/24/19
17:45
Hot Stocks
FB Financial provides update on its exit of wholesale mortgage channels »

FB Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$31.11

-0.99 (-3.08%)

17:44
06/24/19
06/24
17:44
06/24/19
17:44
Hot Stocks
Fluor: Stork consortium awarded four-year agreement by Ecopetrol in Colombia »

Fluor announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERYP

Erytech Pharma

$6.69

(0.00%)

17:33
06/24/19
06/24
17:33
06/24/19
17:33
Hot Stocks
Erytech Pharma announces strategic collaboration with SQZ Biotechnologies »

ERYTECH Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$359.98

0.555 (0.15%)

17:33
06/24/19
06/24
17:33
06/24/19
17:33
Hot Stocks
Lockheed Martin awarded $561.80M Army contract »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$35.38

-1.01 (-2.78%)

17:30
06/24/19
06/24
17:30
06/24/19
17:30
Syndicate
The Medicines Co. files to sell $150M of common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHTLY

Metcash

$0.00

(0.00%)

17:30
06/24/19
06/24
17:30
06/24/19
17:30
Downgrade
Metcash rating change at Goldman Sachs »

Metcash downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

, LLL

L3 Technologies

$256.30

(0.00%)

17:28
06/24/19
06/24
17:28
06/24/19
17:28
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

LLL

L3 Technologies

$256.30

(0.00%)

AAXN

Axon

$73.22

-0.12 (-0.16%)

MLAB

Mesa Labs

$227.44

-3.4 (-1.47%)

HRS

Harris

$197.28

-0.07 (-0.04%)

USNA

Usana

$72.41

-0.58 (-0.79%)

LION

Fidelity Southern

$30.18

-0.06 (-0.20%)

ABCB

Ameris Bancorp

$37.76

(0.00%)

XNCR

Xencor

$33.86

-1.31 (-3.72%)

HF

HFF Inc.

$45.25

-0.29 (-0.64%)

JLL

Jones Lang LaSalle

$137.43

-2.075 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 06

    Aug

  • 26

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.